Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.

Cancer biomarkers : section A of Disease markers - 1 Jan 2018

Takeshita Takashi, Yamamoto Yutaka, Yamamoto-Ibusuki Mutsuko, Tomiguchi Mai, Sueta Aiko, Iwase Hirotaka

Abstract excerpt

PURPOSE: Plasma and serum cell-free DNA (cfDNA) are useful sources of tumor DNA, but comparative investigations of the tumor mutational status between them are rare. METHODS: we performed droplet digital PCR assay for representative hotspot mutations in metastatic breast cancer (MBC) (ESR1 and PIK3CA) in serum and plasma cfDNA concurrently extracted from the blood of 33 estrogen receptor-positive MBC patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Estrogen Receptor alpha

Share to Neoplasm Grading

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 29689710
DOI: 10.3233/CBM-171161
PMCID: PMC13078420

Genes

PIK3CA
ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.PMID 29689710Read ↗

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Semantic proximity Read ↗

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer PatientsSemantic proximity Read ↗

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patientsSemantic proximity Read ↗

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.Semantic proximity Read ↗

Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.Semantic proximity Read ↗

Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.Semantic proximity Read ↗

Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.Semantic proximity Read ↗

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer PatientsSemantic proximity Read ↗

Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of PIK3CA hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAsSemantic proximity Read ↗

ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action.Semantic proximity Read ↗

Coupling multiplex pre-amplification and droplet digital PCR for longitudinal monitoring of <i>ESR1</i> and <i>PIK3CA</i> mutations from plasma cell-free DNASemantic proximity Read ↗

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.